Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifampicin versus clofazimine adjunctive regimens for fibrocavitary pulmonary MAC disease
2015-003786-28Phase 3Terminated
- Sponsor
- Radboudumc
- Start
- Oct 2015
- Modality
- Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rifampicin, clofazimine, ethambutol and azithromycin in Mycobacterium avium lung disease and nontuberculous mycobacterial lung disease (2 arms), sponsored by Radboudumc. Primary endpoint: Sputum culture conversion after 6 months of treatment. Started Oct 2015; status: terminated.
02
Drugs
rifampicinclofazimineethambutolazithromycin
03
Conditions
Mycobacterium avium lung diseasenontuberculous mycobacterial lung disease
Beyond the preview
Go deeper on 2015-003786-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003786-28.